Human immune cells can eliminate cancer cells. Anaveon has developed a special antibody to boost the body’s own defense mechanism. The picture shows an electron-microscopic view of one of the immune system’s CD8 killer cells. (Image: NIAID/flickr)

BaseLaunch backed Anaveon received funding

Onur Boyman, an immunologist working at the University Hospital Zurich and UZH, has joined forces with Andreas Katopodis to establish Anaveon, a BaseLaunch participant. Aiming to translate breakthroughs in research in the field of cytokines into new and innovative immunotherapies for cancer. The spin-off has been made possible thanks to support from the UZH Life Sciences Fund.

An article by Stefan Stöcklin, UZH

Immunotherapies are among the most promising approaches to treating cancer. They work on the basis of systematically strengthening the body’s own immune system to eliminate cancer cells. So far they have achieved impressive results, for example in the treatment of melanoma or cancer of the lungs and kidneys.

The newly established spin-off Anaveon also has this high-potential field in its sights: “We’ve developed a special antibody that we’ll now be testing in clinical trials for the treatment of various types of cancer,” explains Onur Boyman, co-founder of the company and director of the Department of Immunology at the University Hospital Zurich. The spin-off has been launched with the help of investment from UZH Life Sciences Fund and the BaseLaunch.

Please click here for the full article.

 

See also about Anaveon

BaseLaunch up to a solid Phase II start

Onur Boyman and Andreas Katopodis featured in our BaseLaunch video